WSTAM
SUPN icon

Wilbanks Smith & Thomas Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32
Closed -$2K – 1195
2018
Q3 		$2K Buy
+32
New +$1.58K ﹤0.01% 1436

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's SUPN Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 32 shares — an estimated $2K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in SUPN in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 32 Supernus Pharmaceuticals shares in Q4 2018, an estimated $2K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Supernus Pharmaceuticals position peaked at $2K in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.